Other

Mtm Laboratories, Ag

Roche Mtm Laboratories Ag

Michael Linnebacher

Ruediger Ridder

Magnus Von Knebel-Doeberitz

Peer Bork

Magnus Von Knebel Doeberitz

Wolfgang Rudy

Johannes Gebert

Stefan Woerner

Yan Ping Yuan

The present invention relates to a pharmaceutical composition, comprising a cell cycle regulatory protein and/or an expressible nucleic acid coding for this in an amount suitable for immunization of an individual against carcinomas and the preliminary stages thereof and common auxiliary agents and/or to the use of a cell cycle regulatory protein and/or an expressible nucleic acid coding for this to immunize an individual against carcinomas and the preliminary stages thereof.

Immunization of an individual against carcinomas and the preliminary stages thereof

The present invention relates to compounds and methods useful for the detection and treatment of disorders associated with frameshift mutations in coding microsatellite regions. The compounds and methods are applicable in cancers, especially of DNA mismatch repair deficient (MMR) sporadic tumors and HNPCC associated tumors. The compounds are useful for detection of disorders and in therapy such as immuno-therapy. The diagnostic methods relate to diagnosis and prognostic assessment of disorders associated with frameshift polypeptides originating from frameshift mutations in coding microsatellite regions of genes based on the detection of immunological entities directed against said frameshift polypeptides in body fluids. With respect to the treatment of cancer, the invention pertains to methods which use immuno therapy with combinatorial mixtures of tumor specific frameshift peptides to elicit a cytotoxic T-cell response specifically directed against tumor cells for prevention and curative treatment of cancers and precancers.

Compounds and methods useful for detection and treatment of cancer

The present invention relates to compounds and methods useful for the detection and treatment of disorders associated with frameshift mutations in coding microsatellite regions. The compounds and methods are applicable in cancers, especially of DNA mismatch repair deficient (MMR) sporadic tumors and HNPCC associated tumors. The compounds disclosed in the invention are useful for detection of disorders and in therapy such as e.g. immuno-therapy. The diagnostic methods relate to diagnosis and prognostic assessment of disorders associated with frameshift polypeptides originating from frameshift mutations in coding microsatellite regions of genes based on the detection of immunological entities directed against said frameshift polypeptides in body fluids. With respect to the treatment of cancer, especially of DNA mismatch repair deficient (MMR) sporadic tumors and HNPCC associated tumors, the invention pertains to methods which use immuno therapy with combinatorial mixtures of tumor specific frameshift peptides to elicit a cytotoxic T-cell response specifically directed against tumor cells for use in prevention as well as in curative treatment of cancers and precancers.

Neopeptides and methods useful for detection and treatment of cancer

Growing community of inventors

Stennweiler, Germany

Michael Linnebacher